Related Experiment Video
Updated: May 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura
G Le Guenno1, M Ruivard, L Charra
1Department of Internal Medicine, Hotel-Dieu, CHU, Clermont-Ferrand, France. gleguenno@chu-clermontferrand.fr
Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti-CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1-20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab-induced serum sickness.
Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti-CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1-20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab-induced serum sickness.
Related Concept Videos
Hypersensitivity Reactions: Immune-Complex Reactions
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Hypersensitivity Reactions: Cytolytic Reactions
Drug Toxicity: Allergic Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
